Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Update on EU-funded Nipah virus vaccine project

By HC Andersen Capital
ExpreS2ion Biotech Holding

On 1 December 2023, ExpreS2ion Biotechnologies announced the award of a grant that amounts to EUR 8m (approx. SEK 90m) for the VICI-Disease consortium. 53% of the amount is a direct contribution to ExpreS2ion’s part of the project costs. The development project aims to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate. This is the first strong signal of ExpreS2ion’s new strategy direction, leveraging the platform to advance assets with shorter development timelines and less costs to value creation.

ExpreS2ion Biotechnologies’ CEO Bent Frandsen will dig a bit deeper into the news about the Nipah virus vaccine project on 14 December 2023 at 10:00 in a virtual live event.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 15:03 8/12-2023.

Recent videos

GreenMobility: What is the investment case in driverless cars
2025-12-05 08:00 GreenMobility
UPM and Sappi are planning a joint venture in graphic papers
2025-12-04 13:00 UPM-Kymmene
GreenMobility: How far away are driverless cars in Denmark
2025-12-04 11:32 GreenMobility
Systemair, Audiocast, Q2'25/26
2025-12-04 09:00 Systemair
Hafnia – Presentation of the quarterly report for Q3 2025
2025-12-02 11:00 Hafnia
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.